{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:08:38Z","timestamp":1791461318345,"version":"4.3.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,2,12]],"date-time":"2015-02-12T00:00:00Z","timestamp":1423699200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1038\/hr.2015.2","type":"journal-article","created":{"date-parts":[[2015,2,12]],"date-time":"2015-02-12T06:56:06Z","timestamp":1423724166000},"page":"252-259","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Angiotensin II receptor blockers decrease serum concentration of fatty acid-binding protein 4 in patients with hypertension"],"prefix":"10.1038","volume":"38","author":[{"given":"Masato","family":"Furuhashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Mita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihito","family":"Moniwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Hoshina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shutaro","family":"Ishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Fuseya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Shimamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuji","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,2,12]]},"reference":[{"key":"BFhr20152_CR1","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nrd2589","volume":"7","author":"M Furuhashi","year":"2008","unstructured":"Furuhashi M, Hotamisligil GS . Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov 2008; 7: 489\u2013503.","journal-title":"Nat Rev Drug Discov"},{"key":"BFhr20152_CR2","doi-asserted-by":"publisher","first-page":"642612","DOI":"10.4061\/2011\/642612","volume":"2011","author":"M Furuhashi","year":"2011","unstructured":"Furuhashi M, Ishimura S, Ota H, Miura T . Lipid chaperones and metabolic inflammation. Int J Inflam 2011; 2011: 642612.","journal-title":"Int J Inflam"},{"key":"BFhr20152_CR3","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1126\/science.274.5291.1377","volume":"274","author":"GS Hotamisligil","year":"1996","unstructured":"Hotamisligil GS, Johnson RS, Distel RJ, Ellis R, Papaioannou VE, Spiegelman BM . Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 1996; 274: 1377\u20131379.","journal-title":"Science"},{"key":"BFhr20152_CR4","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/89076","volume":"7","author":"L Makowski","year":"2001","unstructured":"Makowski L, Boord JB, Maeda K, Babaev VR, Uysal KT, Morgan MA, Parker RA, Suttles J, Fazio S, Hotamisligil GS, Linton MF . Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med 2001; 7: 699\u2013705.","journal-title":"Nat Med"},{"key":"BFhr20152_CR5","first-page":"2640","volume":"118","author":"M Furuhashi","year":"2008","unstructured":"Furuhashi M, Fucho R, Gorgun CZ, Tuncman G, Cao H, Hotamisligil GS . Adipocyte\/macrophage fatty acid-binding proteins contribute to metabolic deterioration through actions in both macrophages and adipocytes in mice. J Clin Invest 2008; 118: 2640\u20132650.","journal-title":"J Clin Invest"},{"key":"BFhr20152_CR6","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/nature05844","volume":"447","author":"M Furuhashi","year":"2007","unstructured":"Furuhashi M, Tuncman G, Gorgun CZ, Makowski L, Atsumi G, Vaillancourt E, Kono K, Babaev VR, Fazio S, Linton MF, Sulsky R, Robl JA, Parker RA, Hotamisligil GS . Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature 2007; 447: 959\u2013965.","journal-title":"Nature"},{"key":"BFhr20152_CR7","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1373\/clinchem.2005.062463","volume":"52","author":"A Xu","year":"2006","unstructured":"Xu A, Wang Y, Xu JY, Stejskal D, Tam S, Zhang J, Wat NM, Wong WK, Lam KS . Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem 2006; 52: 405\u2013413.","journal-title":"Clin Chem"},{"key":"BFhr20152_CR8","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.cmet.2013.04.012","volume":"17","author":"H Cao","year":"2013","unstructured":"Cao H, Sekiya M, Ertunc ME, Burak MF, Mayers JR, White A, Inouye K, Rickey LM, Ercal BC, Furuhashi M, Tuncman G, Hotamisligil GS . Adipocyte lipid chaperone AP2 is a secreted adipokine regulating hepatic glucose production. Cell Metab 2013; 17: 768\u2013778.","journal-title":"Cell Metab"},{"key":"BFhr20152_CR9","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/oby.20954","volume":"23","author":"T Mita","year":"2015","unstructured":"Mita T, Furuhashi M, Hiramitsu S, Ishii J, Hoshina K, Ishimura S, Fuseya T, Watanabe Y, Tanaka M, Ohno K, Akasaka H, Ohnishi H, Yoshida H, Saitoh S, Shimamoto K, Miura T . FABP4 is secreted from adipocytes by adenyl cyclase-PKA- and guanylyl cyclase-PKG-dependent lipolytic mechanisms. Obesity 2015; 23: 359\u2013367.","journal-title":"Obesity"},{"key":"BFhr20152_CR10","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1161\/CIRCRESAHA.109.200501","volume":"105","author":"V Lamounier-Zepter","year":"2009","unstructured":"Lamounier-Zepter V, Look C, Alvarez J, Christ T, Ravens U, Schunck WH, Ehrhart-Bornstein M, Bornstein SR, Morano I . Adipocyte fatty acid-binding protein suppresses cardiomyocyte contraction: a new link between obesity and heart disease. Circ Res 2009; 105: 326\u2013334.","journal-title":"Circ Res"},{"key":"BFhr20152_CR11","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1161\/CIRCULATIONAHA.106.647503","volume":"115","author":"A Xu","year":"2007","unstructured":"Xu A, Tso AW, Cheung BM, Wang Y, Wat NM, Fong CH, Yeung DC, Janus ED, Sham PC, Lam KS . Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation 2007; 115: 1537\u20131543.","journal-title":"Circulation"},{"key":"BFhr20152_CR12","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1161\/ATVBAHA.107.146274","volume":"27","author":"DC Yeung","year":"2007","unstructured":"Yeung DC, Xu A, Cheung CW, Wat NM, Yau MH, Fong CH, Chau MT, Lam KS . Serum adipocyte fatty acid-binding protein levels were independently associated with carotid atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27: 1796\u20131802.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"BFhr20152_CR13","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/ajh.2012.88","volume":"25","author":"H Ota","year":"2012","unstructured":"Ota H, Furuhashi M, Ishimura S, Koyama M, Okazaki Y, Mita T, Fuseya T, Yamashita T, Tanaka M, Yoshida H, Shimamoto K, Miura T . Elevation of fatty acid-binding protein 4 is predisposed by family history of hypertension and contributes to blood pressure elevation. Am J Hypertens 2012; 25: 1124\u20131130.","journal-title":"Am J Hypertens"},{"key":"BFhr20152_CR14","doi-asserted-by":"publisher","first-page":"e81318","DOI":"10.1371\/journal.pone.0081318","volume":"8","author":"S Ishimura","year":"2013","unstructured":"Ishimura S, Furuhashi M, Watanabe Y, Hoshina K, Fuseya T, Mita T, Okazaki Y, Koyama M, Tanaka M, Akasaka H, Ohnishi H, Yoshida H, Saitoh S, Miura T . Circulating levels of fatty acid-binding protein family and metabolic phenotype in the general population. PLoS ONE 2013; 8: e81318.","journal-title":"PLoS ONE"},{"key":"BFhr20152_CR15","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12933-014-0126-7","volume":"13","author":"T Fuseya","year":"2014","unstructured":"Fuseya T, Furuhashi M, Yuda S, Muranaka A, Kawamukai M, Mita T, Ishimura S, Watanabe Y, Hoshina K, Tanaka M, Ohno K, Akasaka H, Ohnishi H, Yoshida H, Saitoh S, Shimamoto K, Miura T . Elevation of circulating fatty acid-binding protein 4 is independently associated with left ventricular diastolic dysfunction in a general population. Cardiovasc Diabetol 2014; 13: 126.","journal-title":"Cardiovasc Diabetol"},{"key":"BFhr20152_CR16","doi-asserted-by":"publisher","first-page":"e27356","DOI":"10.1371\/journal.pone.0027356","volume":"6","author":"M Furuhashi","year":"2011","unstructured":"Furuhashi M, Ishimura S, Ota H, Hayashi M, Nishitani T, Tanaka M, Yoshida H, Shimamoto K, Hotamisligil GS, Miura T . Serum fatty acid-binding protein 4 is a predictor of cardiovascular events in end-stage renal disease. PLoS ONE 2011; 6: e27356.","journal-title":"PLoS ONE"},{"key":"BFhr20152_CR17","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1161\/ATVBAHA.112.248609","volume":"32","author":"M von Eynatten","year":"2012","unstructured":"von Eynatten M, Breitling LP, Roos M, Baumann M, Rothenbacher D, Brenner H . Circulating adipocyte fatty acid-binding protein levels and cardiovascular morbidity and mortality in patients with coronary heart disease: a 10-year prospective study. Arterioscler Thromb Vasc Biol 2012; 32: 2327\u20132335.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"BFhr20152_CR18","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/hr.2013.141","volume":"37","author":"H Yoshida","year":"2014","unstructured":"Yoshida H, Akasaka H, Saitoh S, Shimamoto K, Miura T . Comparative effects of telmisartan and valsartan as add-on agents for hypertensive patients with morning blood pressure insufficiently controlled by amlodipine monotherapy. Hypertens Res 2014; 37: 225\u2013231.","journal-title":"Hypertens Res"},{"key":"BFhr20152_CR19","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A, Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982\u2013992.","journal-title":"Am J Kidney Dis"},{"key":"BFhr20152_CR20","first-page":"E214","volume":"237","author":"RA DeFronzo","year":"1979","unstructured":"DeFronzo RA, Tobin JD, Andres R . Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: E214\u2013E223.","journal-title":"Am J Physiol"},{"key":"BFhr20152_CR21","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1161\/01.HYP.0000078490.59735.6E","volume":"42","author":"M Furuhashi","year":"2003","unstructured":"Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N, Yoshida D, Shimamoto K . Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003; 42: 76\u201381.","journal-title":"Hypertension"},{"key":"BFhr20152_CR22","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1161\/01.HYP.0000123072.34629.57","volume":"43","author":"SC Benson","year":"2004","unstructured":"Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW . Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43: 993\u20131002.","journal-title":"Hypertension"},{"key":"BFhr20152_CR23","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1161\/01.CIR.0000127955.36250.65","volume":"109","author":"M Schupp","year":"2004","unstructured":"Schupp M, Janke J, Clasen R, Unger T, Kintscher U . Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004; 109: 2054\u20132057.","journal-title":"Circulation"},{"key":"BFhr20152_CR24","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1007\/s00380-010-0060-x","volume":"26","author":"T Miyoshi","year":"2011","unstructured":"Miyoshi T, Doi M, Hirohata S, Kamikawa S, Usui S, Ogawa H, Sakane K, Izumi R, Ninomiya Y, Kusachi S . Olmesartan reduces arterial stiffness and serum adipocyte fatty acid-binding protein in hypertensive patients. Heart Vessels 2011; 26: 408\u2013413.","journal-title":"Heart Vessels"},{"issue":"Suppl 1","key":"BFhr20152_CR25","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1007\/s11906-001-0067-x","volume":"3","author":"H Krum","year":"2001","unstructured":"Krum H . Differentiation in the angiotensin II receptor 1 blocker class on autonomic function. Curr Hypertens Rep 2001; 3 (Suppl 1): S17\u2013S23.","journal-title":"Curr Hypertens Rep"},{"key":"BFhr20152_CR26","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/hr.2012.196","volume":"36","author":"H Takagi","year":"2013","unstructured":"Takagi H, Mizuno Y, Yamamoto H, Goto SN, Umemoto T, All-Literature Investigation of Cardiovascular Evidence G. Effects of telmisartan therapy on interleukin-6 and tumor necrosis factor-alpha levels: a meta-analysis of randomized controlled trials. Hypertens Res 2013; 36: 368\u2013373.","journal-title":"Hypertens Res"},{"key":"BFhr20152_CR27","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/hr.2014.51","volume":"37","author":"AU Hasan","year":"2014","unstructured":"Hasan AU, Ohmori K, Hashimoto T, Kamitori K, Yamaguchi F, Ishihara Y, Ishihara N, Noma T, Tokuda M, Kohno M . Valsartan ameliorates the constitutive adipokine expression pattern in mature adipocytes: a role for inverse agonism of the angiotensin II type 1 receptor in obesity. Hypertens Res 2014; 37: 621\u2013628.","journal-title":"Hypertens Res"},{"key":"BFhr20152_CR28","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.plipres.2009.05.001","volume":"48","author":"M Lafontan","year":"2009","unstructured":"Lafontan M, Langin D . Lipolysis and lipid mobilization in human adipose tissue. Prog Lipid Res 2009; 48: 275\u2013297.","journal-title":"Prog Lipid Res"},{"key":"BFhr20152_CR29","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.2169\/internalmedicine.51.7408","volume":"51","author":"S Shimoda","year":"2012","unstructured":"Shimoda S, Goto R, Furukawa N, Tsuruzoe K, Kawashima J, Iwashita S, Maeda T, Ichimori S, Ichinose K, Nishida K, Araki E . Effects of olmesartan, an angiotensin II receptor blocker, on peripheral insulin sensitivity in Japanese subjects with type 2 diabetes and hypertension. Intern Med 2012; 51: 2091\u20132096.","journal-title":"Intern Med"},{"key":"BFhr20152_CR30","doi-asserted-by":"publisher","first-page":"845","DOI":"10.2337\/dc10-2224","volume":"34","author":"NJ van der Zijl","year":"2011","unstructured":"van der Zijl NJ, Moors CC, Goossens GH, Hermans MM, Blaak EE, Diamant M . Valsartan improves {beta}-cell function and insulin sensitivity in subjects with impaired glucose metabolism: a randomized controlled trial. Diabetes Care 2011; 34: 845\u2013851.","journal-title":"Diabetes Care"},{"key":"BFhr20152_CR31","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1055\/s-0029-1237359","volume":"41","author":"R Fogari","year":"2009","unstructured":"Fogari R, Zoppi A, Ferrari I, Mugellini A, Preti P, Lazzari P, Derosa G . Comparative effects of telmisartan and eprosartan on insulin sensitivity in the treatment of overweight hypertensive patients. Horm Metab Res 2009; 41: 893\u2013898.","journal-title":"Horm Metab Res"},{"key":"BFhr20152_CR32","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1161\/01.HYP.0000036448.44066.53","volume":"40","author":"AM Sharma","year":"2002","unstructured":"Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC . Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002; 40: 609\u2013611.","journal-title":"Hypertension"},{"key":"BFhr20152_CR33","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1097\/00004872-200410000-00021","volume":"22","author":"M Furuhashi","year":"2004","unstructured":"Furuhashi M, Ura N, Takizawa H, Yoshida D, Moniwa N, Murakami H, Higashiura K, Shimamoto K . Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity. J Hypertens 2004; 22: 1977\u20131982.","journal-title":"J Hypertens"},{"key":"BFhr20152_CR34","doi-asserted-by":"publisher","first-page":"e150","DOI":"10.1016\/j.atherosclerosis.2007.04.045","volume":"195","author":"A Cabre","year":"2007","unstructured":"Cabre A, Lazaro I, Girona J, Manzanares JM, Marim\u00f3n F, Plana N, Heras M, Masana L . Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients. Atherosclerosis 2007; 195: e150\u2013e158.","journal-title":"Atherosclerosis"},{"key":"BFhr20152_CR35","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0140-6736(07)60108-1","volume":"369","author":"WJ Elliott","year":"2007","unstructured":"Elliott WJ, Meyer PM . Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369: 201\u2013207.","journal-title":"Lancet"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/hr20152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/hr20152","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/hr20152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:15:21Z","timestamp":1684430121000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/hr20152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,12]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["BFhr20152"],"URL":"https:\/\/doi.org\/10.1038\/hr.2015.2","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,12]]},"assertion":[{"value":"1 September 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}